CRC Press Practical Phlebology: Deep Vein Thrombosis

The latest volume in the Practical Phlebology series, Deep Vein Thrombosis provides trainee and practicing physicians with the ideal illustrative guide to the etiology, diagnosis, and management of deep vein thrombosis (DVT). Based on peer-reviewed literature and quality clinical trials, the book is also an essential resource for academicians. Topics include: Epidemiology, natural history, and etiology of DVT DVT prophylaxis Diagnostic techniques Anticoagulation, thrombus removal, catheter-based interventions, and thrombolysis Inferior vena cava filters Heparin-induced thrombocytopenia Femoral endovenectomy and endoluminal recanalization Review "This is an invaluable book for clinicians wishing to increase their knowledge about DVT and how to care for patients with this disease process. … well written with complete yet understandable explanations of the disease process and how to treat patients with each type of DVT." (4 stars)―Courtney M Daly, MD (Northwestern University Feinberg School of Medicine) in Doody’s Review Service About the Author Anthony J. Comerot, MD, FACS, FACC, is the director of the Jobst Vascular Institute at Toledo Hospital in Ohio and adjunct professor of surgery at the University of Michigan. He received his medical degree from Temple University School of Medicine in Philadelphia, Pennsylvania, and completed his general surgery residency at Temple University Hospital and his vascular surgery fellowship at Good Samaritan Hospital, Cincinnati, Ohio. Dr. Comerota has been a major contributor to the development of some of the newest forms of treatment for vascular disease and has been the principal investigator of seven major national trials and a co-investigator of numerous others. His research interests span a broad range of arterial and venous disorders, including the management of acute DVT, therapeutic angiogenesis, noninvasive diagnosis of vascular disease, development of new devices, new drug development, and the effects of platelet-inhibiting drugs. He has received over $5 million in research funding, including support from the National Institutes of Health (NIH), the American Heart Association, and the American Diabetes Association.